Nuveen Asset Management, LLC Gritstone Bio, Inc. Transaction History

Nuveen Asset Management, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.28 - $2.85 $1,242 - $2,767	-971 Reduced 0.28%	340,478 $694,000
Q2 2023 Aug 14, 2023	BUY	$1.66 - $3.03 $566,805 - $1.03 Million	341,449 New	341,449 $665,000
Q2 2022 Aug 15, 2022	SELL	$1.77 - $4.34 $1.35 Million - $3.3 Million	-760,986 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.03 - $12.19 $879,978 - $2.66 Million	-218,357 Reduced 22.3%	760,986 $3.47 Million
Q4 2021 Feb 14, 2022	BUY	$8.76 - $13.71 $2 Million - $3.14 Million	228,814 Added 30.49%	979,343 $11.3 Million
Q3 2021 Nov 12, 2021	BUY	$6.41 - $13.54 $2.23 Million - $4.71 Million	347,733 Added 86.33%	750,529 $8.63 Million
Q2 2021 Aug 16, 2021	BUY	$8.13 - $10.2 $2.19 Million - $2.75 Million	269,270 Added 201.66%	402,796 $3.68 Million
Q1 2021 May 17, 2021	SELL	$4.07 - $27.11 $97,045 - $646,410	-23,844 Reduced 15.15%	133,526 $1.26 Million
Q4 2020 Feb 16, 2021	SELL	$2.57 - $4.22 $5,756 - $9,452	-2,240 Reduced 1.4%	157,370 $620,000
Q3 2020 Nov 16, 2020	BUY	$2.63 - $8.09 $56,794 - $174,703	21,595 Added 15.65%	159,610 $423,000
Q2 2020 Aug 14, 2020	BUY	$5.69 - $8.17 $70,823 - $101,691	12,447 Added 9.91%	138,015 $916,000
Q1 2020 May 14, 2020	BUY	$5.47 - $11.3 $49,443 - $102,140	9,039 Added 7.76%	125,568 $730,000
Q4 2019 Feb 14, 2020	SELL	$7.07 - $11.61 $7,458 - $12,248	-1,055 Reduced 0.9%	116,529 $1.05 Million
Q3 2019 Nov 14, 2019	BUY	$8.45 - $12.28 $428,507 - $622,731	50,711 Added 75.83%	117,584 $1.02 Million
Q2 2019 Aug 15, 2019	BUY	$9.2 - $15.7 $615,231 - $1.05 Million	66,873 New	66,873 $745,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.